David Amsalem

“First on Rekorlev, can you talk about prescriber breadth and depth? And sorry if I missed this, but can you give color on how many prescribers there are and repeat prescribers?”

“First on IOhexol with the additional SKUs approved, can you talk about how big of an opportunity that could be, not just this year, but also in 27, if you can quantify that, and your views on how long that could be a situation where there's limited competition and a similar question on land rear tide can you just…”

“First on the mix for Cortrofin, can you talk to how much of your growth is coming from the non-gout settings like pulmonology slash sarcoidosis and ophthalmology and how much of the mix is in those other high growth settings other than gout.”

“So firstly, looking at ReCoreLiv, can you help give us a better sense of what kinds of patients are getting the product and how are you thinking about other subgroups of patients beyond uncontrolled hypertension and uncontrolled type 2 diabetes?”

“So on the orexin programs beyond sleep-wake, in ADHD, can you talk about your thought process regarding development as monotherapy versus adjunctive therapy in ADHD, and what preclinical data you can point to that gives you confidence that a monotherapy approach makes sense.”